Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Financing Activities for 4 consecutive years, with -$97000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 100.37% to -$97000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$288000.0 through Dec 2025, down 100.16% year-over-year, with the annual reading at -$288000.0 for FY2025, 100.16% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$97000.0 at Phathom Pharmaceuticals, up from -$271000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $212.0 million in Q4 2023, with the low at -$271000.0 in Q3 2025.
  • Average Cash from Financing Activities over 4 years is $47.9 million, with a median of $19.3 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 938800.0% in 2024, then tumbled 100.37% in 2025.
  • Over 4 years, Cash from Financing Activities stood at $24.6 million in 2022, then soared by 761.9% to $212.0 million in 2023, then plummeted by 87.71% to $26.0 million in 2024, then crashed by 100.37% to -$97000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$97000.0, -$271000.0, and $80000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.